ProfileGDS5678 / 1415789_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 83% 84% 84% 81% 81% 83% 80% 82% 81% 82% 82% 82% 82% 82% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.0585583
GSM967853U87-EV human glioblastoma xenograft - Control 26.2459384
GSM967854U87-EV human glioblastoma xenograft - Control 36.3061484
GSM967855U87-EV human glioblastoma xenograft - Control 45.9543781
GSM967856U87-EV human glioblastoma xenograft - Control 55.8485981
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.9221483
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.4843580
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.9311482
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.7645781
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.9304482
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.9898582
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.0411982
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.9260782
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.9308982